ERBB2 and heart disorder: Firstly, the patient characteristics could not be extracted, including underlying heart disease, baseline LVEF value, cumulative doses of anthracycline, cumulative treatment cycles of previous HER2-targeted agents, etc. Furthermore, the timing, duration, and prognosis of CEs were also unavailable.